REG - Haleon PLC Haleon UK Capital Haleon Netherlands - Haleon plc: EMTN bond offering

HALEONAnnouncement

12/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240912:nRSL8576Da&default-theme=true

RNS Number : 8576D  Haleon PLC  12 September 2024

 

 

Haleon plc: EMTN bond offering

 

12 September 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN)
today announces that, on 11 September 2024, its wholly-owned subsidiary,
Haleon UK Capital plc, successfully priced two notes under its Euro Medium
Term Note ("EMTN") programme (the "Offering"). The Offering is expected to
close on 18 September 2024, subject to customary closing conditions.

 

The Offering consisted of the following notes, issued by Haleon UK Capital plc
and fully and unconditionally guaranteed by the Company:

 

·      €750,000,000 of fixed rate notes with a coupon of 2.875%
maturing on 18 September 2028; and

 

·      £300,000,000 of fixed rate notes with a coupon of 4.625%
maturing on 18 September 2033 (together, the "Notes")

 

The Company expects to use the net proceeds of the Offering for general
corporate purposes including partial repayment of the $1.75bn bond maturing in
March 2025.

 

Barclays, Bank of America, BNP Paribas and JP Morgan acted as joint
book-running managers on the transaction.

 

The Notes will be issued under Haleon UK Capital plc's and Haleon Netherlands
Capital B.V.'s £10,000,000,000 EMTN programme and admitted to trading on the
International Securities Market of the London Stock Exchange.

 

The Notes have not been registered under the U.S. Securities Act of 1933 and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration.

 

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy the Notes described herein, nor shall there be any sale of
these Notes in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities
laws of any such jurisdiction.

 

 

Amanda Mellor

Company Secretary

 

 

Enquiries

 

 Investors                                    Media

 Sonya Ghobrial          +44 7392 784784      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Gemma Thomas        +44 7985 175048
 Emma White              +44 7823 523562

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODLBMLTMTABBFI